A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
24actual
Sites
2
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-11-30 | actual | When the study began enrolling |
| Primary completion | 2025-09-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-24 | actual | The whole study's end, after follow-up |
| First posted | 2021-11-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors
Intervention
- Drug: BMS-986213
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AEs)
measured Approximately 3 years
Number of Participants with Immune-mediated Adverse Events (IMAEs)
measured Approximately 3 years
Number of Participants with Serious Adverse Events (SAEs)
measured Approximately 3 years
Number of Deaths
measured Approximately 3 years
Number of Participants with AEs Leading to Discontinuation
measured Approximately 3 years
Number of Participants with Laboratory Abnormalities
measured Approximately 3 years
Maximum Observed Plasma Concentration (Cmax) of Relatlimab
measured Approximately 3 years
Time of Maximum Observed Plasma Concentration (Tmax) of Relatlimab
measured Approximately 3 years
Trough Observed Plasma Concentration (Ctrough) of Relatlimab
measured Approximately 3 years
Concentration of Relatlimab at the end of a dosing interval (Ctau)
measured Approximately 3 years
Average concentration of Relatlimab over a dosing interval (Cavg(TAU))
measured Approximately 3 years
Area under the concentration-time curve in one dosing interval (AUC(TAU)) of Relatlimab
measured Approximately 3 years
Total Body Clearance (CLT) of Relatlimab
measured Approximately 3 years
Observed Concentration of Relatlimab at End of Infusion (Ceoi)
measured Approximately 3 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed